OBJECTIVES: To estimate the incidence of metastatic breast cancer (MBC) in Australian women with an initial diagnosis of non-metastatic breast cancer. DESIGN, SETTING AND PARTICIPANTS: A population-based cohort study of all women with non-metastatic breast cancer registered on the New South Wales Central Cancer Register (CCR) in 2001 and 2002 who received care in a NSW hospital. MAIN OUTCOME MEASURES: 5-year cumulative incidence of MBC; prognostic factors for MBC. RESULTS: MBC was recorded within 5 years in 218 of 4137 women with localised node-negative disease (5-year cumulative incidence, 5.3%; 95% CI, 4.6%-6.0%); and 455 of 2507 women with regional disease (5-year cumulative incidence, 18.1%; 95% CI, 16.7%-19.7%). The hazard rate for developing MBC was highest in the second year after the initial diagnosis of breast cancer. Determinants of increased risk of MBC were regional disease at diagnosis, age less than 50 years and living in an area of lower socio-economic status. CONCLUSIONS: Our Australian population-based estimates are valuable when communicating average MBC risks to patients and planning clinical services and trials. Women with node-negative disease have a low risk of developing MBC, consistent with outcomes of adjuvant clinical trials. Regional disease at diagnosis remains an important prognostic factor.
OBJECTIVES: To estimate the incidence of metastatic breast cancer (MBC) in Australian women with an initial diagnosis of non-metastatic breast cancer. DESIGN, SETTING AND PARTICIPANTS: A population-based cohort study of all women with non-metastatic breast cancer registered on the New South Wales Central Cancer Register (CCR) in 2001 and 2002 who received care in a NSW hospital. MAIN OUTCOME MEASURES: 5-year cumulative incidence of MBC; prognostic factors for MBC. RESULTS:MBC was recorded within 5 years in 218 of 4137 women with localised node-negative disease (5-year cumulative incidence, 5.3%; 95% CI, 4.6%-6.0%); and 455 of 2507 women with regional disease (5-year cumulative incidence, 18.1%; 95% CI, 16.7%-19.7%). The hazard rate for developing MBC was highest in the second year after the initial diagnosis of breast cancer. Determinants of increased risk of MBC were regional disease at diagnosis, age less than 50 years and living in an area of lower socio-economic status. CONCLUSIONS: Our Australian population-based estimates are valuable when communicating average MBC risks to patients and planning clinical services and trials. Women with node-negative disease have a low risk of developing MBC, consistent with outcomes of adjuvant clinical trials. Regional disease at diagnosis remains an important prognostic factor.
Authors: Jasmine Yee; Glen M Davis; Jane M Beith; Nicholas Wilcken; David Currow; Jon Emery; Jane Phillips; Andrew Martin; Rina Hui; Michelle Harrison; Eva Segelov; Sharon L Kilbreath Journal: J Cancer Surviv Date: 2014-07-02 Impact factor: 4.442
Authors: Samuel Onyinyechukwu Azubuike; Louise Hayes; Linda Sharp; Adewumi Alabi; Rasaaq Oyesegun; Richard McNally Journal: Pan Afr Med J Date: 2022-03-04
Authors: R G Koleva-Kolarova; M J W Greuter; M van Kruchten; K M Vermeulen; T Feenstra; E Buskens; A W J M Glaudemans; E F J de Vries; E G E de Vries; G A P Hospers; G H de Bock Journal: Br J Cancer Date: 2015-04-16 Impact factor: 7.640
Authors: Rositsa G Koleva-Kolarova; Marcel J W Greuter; Talitha L Feenstra; Karin M Vermeulen; Erik F J de Vries; David Parkin; Erik Buskens; Geertruida H de Bock Journal: Oncotarget Date: 2018-04-13
Authors: Paramita Dasgupta; Peter D Baade; Danny R Youlden; Gail Garvey; Joanne F Aitken; Isabella Wallington; Jennifer Chynoweth; Helen Zorbas; Philippa H Youl Journal: BMJ Open Date: 2018-04-29 Impact factor: 2.692
Authors: Daniel Xin Zhang; Xuan T T Dang; Luyen Tien Vu; Claudine Ming Hui Lim; Eric Yew Meng Yeo; Brenda Wan Shing Lam; Sai Mun Leong; Noorjehan Omar; Thomas Choudary Putti; Yu Chen Yeh; Victor Ma; Jia-Yuan Luo; William C Cho; Gang Chen; Victor Kwan Min Lee; Andrew Grimson; Minh T N Le Journal: J Extracell Vesicles Date: 2022-08
Authors: Natalia Kunst; Fernando Alarid-Escudero; Eline Aas; Veerle M H Coupé; Deborah Schrag; Karen M Kuntz Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-09-30 Impact factor: 4.254
Authors: Sarah J Lord; Belinda E Kiely; Sallie-Anne Pearson; Benjamin Daniels; Dianne L O'Connell; Jane Beith; Max K Bulsara; Nehmat Houssami Journal: BMJ Open Date: 2019-02-01 Impact factor: 2.692